Gearing up t cell immunotherapy in cervical cancer

The World Health Organization (WHO) estimates more 270000 deaths annually by cervical cancer. Present vaccines are prophylactic in nature which cannot treat huge bulk of cervical cancer patients worldwide. Available therapies like radiotherapy, chemotherapy or surgery are not effective in high grade lesion and hence, there is an unmet medical need for an effective form of therapy. T cells play a significant role in cervical cancer pathogenesis as Human Papilloma Virus (HPV) uses multiple mechanisms that dodge host T cell immune-surveillance aiding in persistence of infection and establishment of cancer.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research